Prolonged correction of serum phosphorus in adults with x-linked hypophosphatemia using monthly doses of KRN23

Erik A. Imel, Xiaoping Zhang, Mary D. Ruppe, Thomas J. Weber, Mark A. Klausner, Takahiro Ito, Maria Vergeire, Jeffrey S. Humphrey, Francis H. Glorieux, Anthony A. Portale, Karl Insogna, Munro Peacock, Thomas O. Carpenter

Research output: Contribution to journalArticle

70 Scopus citations


Context: In X-linked hypophosphatemia (XLH), elevated fibroblast growth factor 23 (FGF23) decreases the renal tubular maximum reabsorption rate of phosphate/glomerular filtration rate (TmP/GFR) and serum inorganic phosphorus (Pi), resulting in rickets and/or osteomalacia. Objective: The objective was to test the hypothesis that monthly KRN23 (anti-FGF23 antibody) would safely improve serum Pi in adults with XLH. Design: Two sequential open-label phase 1/2 studies were done. Setting: Six academic medical centers were used. Participants: Twenty-eight adults with XLH participated in a 4-month dose-escalation study (0.05- 0.6 mg/kg); 22 entered a 12-month extension study (0.1-1 mg/kg). Intervention: KRN23 was injected sc every 28 days. Main Outcome Measure: The main outcome measure was the proportion of subjects attaining normal serum Pi and safety. Results: At baseline, mean TmP/GFR, serum Pi, and 1,25-dihydroxyvitamin D [1,25(OH)2D] were 1.6±0.4 mg/dL, 1.9±0.3 mg/dL, and 36.6±14.3 pg/mL, respectively. During dose escalation, TmP/GFR, Pi, and 1,25(OH)2D increased, peaking at 7 days for TmP/GFR and Pi and at 3-7 days for 1,25(OH)2D, remaining above (TmP/GFR, Pi) or near [1,25(OH)2D] pre-dose levels at trough. After each of the four escalating doses, peak Pi was between 2.5 and 4.5 mg/dL in 14.8, 37.0, 74.1, and 88.5% of subjects, respectively. During the 12-month extension, peak Pi was in the normal range for 57.9-85.0% of subjects, and 25%maintained trough Pi levels within the normal range. Serum Pi did not exceed 4.5 mg/dL in any subject. Although 1,25(OH)2D levels increased transiently, mean serum and urinary calcium remained normal. KRN23 treatment increased biomarkers of skeletal turnover and had a favorable safety profile. Conclusions: Monthly KRN23 significantly increased serum Pi, TmP/GFR, and 1,25(OH)2D in all subjects.KRN23has potential for effectively treating XLH.

Original languageEnglish (US)
Pages (from-to)2565-2573
Number of pages9
JournalJournal of Clinical Endocrinology and Metabolism
Issue number7
StatePublished - Jul 1 2015

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Fingerprint Dive into the research topics of 'Prolonged correction of serum phosphorus in adults with x-linked hypophosphatemia using monthly doses of KRN23'. Together they form a unique fingerprint.

  • Cite this

    Imel, E. A., Zhang, X., Ruppe, M. D., Weber, T. J., Klausner, M. A., Ito, T., Vergeire, M., Humphrey, J. S., Glorieux, F. H., Portale, A. A., Insogna, K., Peacock, M., & Carpenter, T. O. (2015). Prolonged correction of serum phosphorus in adults with x-linked hypophosphatemia using monthly doses of KRN23. Journal of Clinical Endocrinology and Metabolism, 100(7), 2565-2573.